After years of back-and-forth, Gilead's CAR-T Yescarta sways England's cost watchdog NICE

There's been a yearslong will-they or won’t-they situation between England’s cost-effectiveness watchdog and Gilead’s Kite—as well as Novartis—for their respective CAR-T therapies. Now, Gilead has finally gotten the drug cost gatekeeper to warm up to its blood cancer cell therapy.